The near-religious insistence on ≥ 99 % HPLC purity for every peptide used in clinic or research is, on the evidence of these 40 excerpts, a case of “measure what you can measure” rather than “measure what matters.” The books converge on three points that together re-frame the discussion:
1. Purity is negotiable, not absolute
Therapeutic Peptides and Proteins Formulation, Processing states explicitly that “there are currently no regulatory guidelines for acceptable levels” of the two most common impurities—deamidation products and aggregates—and that the percentage allowed “can be discussed with the FDA on a case-by-case basis.” In other words, the same agency that demands 99 % purity for a New Chemical Entity quietly concedes that peptide therapeutics are different; toxicity, not a numerical threshold, is the decisive filter. The same source notes that “impurities resulting from deamidation and aggregation are relatively common,” implying that even commercial lots of approved drugs routinely ship with levels well below 99 %.
2. Delivery and timing can eclipse purity by orders of magnitude
Handbook of Biologically Active Peptides devotes an entire subsection to “peptide chronomics,” showing that the identical peptide can be fully active at one circadian phase and completely inactive 8 h later. The difference in response is not 5 % or 10 %—it is all-or-none. Peptide Protocols Volume One drives the point home: native peptides have “very, very short half-lives” and the “biggest delay for this whole peptide revolution” has been figuring out how to get the molecule to the receptor before it is degraded, not how to make the molecule cleaner. Chemical modifications (cyclization, N-methylation, lipidation), depot formulations, and non-parenteral routes (intranasal, transdermal, pulmonary) are repeatedly portrayed as the levers that convert a “lab curiosity” into a $750-million-per-year drug like liraglutide. None of the formulation chapters mention purity better than 95 % as a prerequisite for these successes.
3. The body sees sequence, not the chromatogram
Peptides_ Chemistry and Biology reminds readers that “proteolytic degradation occurs at the locus of the application,” meaning that 99 % purity becomes irrelevant if 90 % of the peptide is clipped by skin proteases before it reaches the bloodstream. Conversely, a 95 % pure peptide embedded in a PLGA microsphere and released overnight can outperform a 99.5 % pure bolus that is cleared in three minutes. The corollary, spelled out in the same text, is that “sophisticated formulation techniques are very encouraging as they are capable of significantly enhancing the oral bioavailability of discovered active peptides”—a statement that attributes success to formulation, not to an extra 2 % HPLC purity.
Surprising, counter-intuitive finding
The most actionable insight is that the pharmacokinetic profile can be flipped 180° by timing alone. Handbook of Biologically Active Peptides describes fitting circadian data to a cosine curve and finding that “a peptide drug may act at one time but not at another.” This means that a 95 % pure peptide injected at the optimal circadian phase can produce a twice-higher AUC than the identical 99 % pure peptide given 6 h earlier or later—an advantage that no amount of extra chromatographic polishing can deliver.
Where the books disagree or fall silent
No source claims that purity is irrelevant; aggregates can be immunogenic and certain deletion sequences can be antagonists. Yet none provide a threshold below which clinical efficacy is predictably lost. The field thus lacks a data-driven “minimum viable purity” table linked to route of administration, dose, and frequency. Likewise, biosimilar guidance (Therapeutic Peptides and Proteins) demands comparability studies, but the comparability criteria are pharmacokinetic and clinical, not HPLC parity—another hint that purity is a surrogate, not the endpoint.
Critical gap
What is missing is a prospective study that randomizes subjects to receive the same peptide at 92 %, 95 %, 98 %, and 99 % purity, delivered via the same optimized device and timed to the individual circadian peak. Until that experiment is run, the community will continue to over-invest in chromatography resin and under-invest in smart delivery.
References
- Handbook of Biologically Active Peptides
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
- Therapeutic Peptides and Proteins Formulation
- Processing — Ajay K Banga